 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12...27282930313233343536373839» |
- |||||| sotorasib (AMG 510) / Amgen
NEW insights on @myESMO #ESMO20 - Jorge J. Nieva, MD (@nievamd) @KeckMedUSC evaluates phase 1 study results of Sotorasib @Amgen, a KRAS inhibitor for lung cancer https://t.co/Zndcf0OpYr (Twitter) - Sep 25, 2020
- sotorasib (AMG 510) / Amgen
[VIRTUAL] AMG 510, a novel small molecule inhibitor of KRAS(G12C), for patients (pts) with advanced gastrointestinal (GI) cancers: Results from the CodeBreaK100 phase I trial (Channel 1) - Sep 24, 2020 - Abstract #ESMOAsia2020ESMO_Asia_259;
P1/2
Funding: Amgen Inc. Clinical trial identification: NCT03600883.
- sotorasib (AMG 510) / Amgen
[VIRTUAL] Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib) (Channel 3) - Sep 24, 2020 - Abstract #ESMOAsia2020ESMO_Asia_231;
P1/2
Funding: Amgen Inc. Clinical trial identification: NCT03600883.
- ||||| sotorasib (AMG 510) / Amgen
Biomarker, Clinical: David S. Hong, MD, on NSCLC: Durability of Clinical Benefit and Biomarkers in Patients Treated With Sotorasib https://t.co/2WoM1CwiI2 #LCSM #ESMO20 #ESMO2020 #oncology #cancer @DavidHongMD (Twitter) - Sep 24, 2020
- |||| sotorasib (AMG 510) / Amgen
I suggested @udai_banerji as your guest to discuss his FRAME study. 65% ORR, 4% TEAE with MEK across multiple KRAS variations, G12D G12V G12A WT. Actually, even G12C data is comparable to AMG510. On the side note, does anything work anymore in singlets? 😎 https://t.co/uNAbiZEePu (Twitter) - Sep 23, 2020
- |||| sotorasib (AMG 510) / Amgen
Preclinical: Looks like AMG510 in animal models wasn't exactly knock your socks off regression. Think a similar picture is emerging with IDH1/2 outside of heme too? Sigh, maybe I'm just trying to be optimistic. https://t.co/Djpbycvjng (Twitter) - Sep 23, 2020
- |||||| sotorasib (AMG 510) / Amgen
Clinical: Join our Dr. David Hong and hear his insights from the 2020 ESMO Virtual Congress, including his presentation of the results from a Phase I clinical trial in KRAS inhibitor sotorasib in non-small lung cancer and colorectal cancer: https://t.co/llXx2jA6C1 @DavidHongMD #EndCancer (Twitter) - Sep 23, 2020
- ||||| sotorasib (AMG 510) / Amgen
BREAKING from @myESMO #ESMO20 - Sotorasib @Amgen shows anticancer activity in KRAS-mutated lung cancer https://t.co/qo5r6lZTmO Results presented by David S. Hong, MD @DavidHongMD @MDAndersonNews (Twitter) - Sep 22, 2020
- |||| sotorasib (AMG 510) / Amgen
Small molecule sotorasib shows encouraging anticancer activity in heavily pretreated advanced solid tumors with KRAS p.G12C mutation. By @DavidHongMD @mgfakih et al. @NEJM https://t.co/kI5FSBnXI9 (Twitter) - Sep 22, 2020
- ||| sotorasib (AMG 510) / Amgen
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors | NEJM https://t.co/fcyaFRK1e4 (Twitter) - Sep 21, 2020
- ||| sotorasib (AMG 510) / Amgen
KRAS is druggable! @davidhongmd @MDAndersonNews KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors | NEJM https://t.co/YlFZiY4tfN (Twitter) - Sep 21, 2020
- ||||| sotorasib (AMG 510) / Amgen
Landmark paper, just published!!!!!! kras inhibition, now need inhibitor for G12D. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors @CathyEngMD @rachnatshroff @agrothey @SWOG @UCHealthNews https://t.co/a0rC7JuaTJ (Twitter) - Sep 21, 2020
- ||||| sotorasib (AMG 510) / Amgen
Biomarker, Clinical: Durability of clinical benefit and biomarkers in patients with advanced non-small cell lung cancer (#NSCLC) treated with AMG 510 (sotorasib) by Dr. David S Hong @OncoAlert @JTrentMDPhD @MehrpouyaMobin (Twitter) - Sep 21, 2020
- |||| sotorasib (AMG 510) / Amgen
Clinical: Not long ago "KRAS" & "targetable" were not mentioned together. Though a fraction of pts w/ RAS mutations, targeting KRAS G12C w/sotorasib is paradigm shift in conversations w/patients re #CRCSM. Congrats @DavidHongMD & @MDAndersonNews team! #endcancer https://t.co/4MfWEYKeqw (Twitter) - Sep 21, 2020
- ||| sotorasib (AMG 510) / Amgen
4/4 KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors including #NSCLC @NEJM #ESMO20 @myESMO @PTarantinoMD @BenWestphalen @BenjaminBesseMD https://t.co/pLSdVw6V3q (Twitter) - Sep 21, 2020
- ||| sotorasib (AMG 510) / Amgen
@davidhongmd @MDAndersonNews KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors | NEJM https://t.co/8ecrqjrqNZ (Twitter) - Sep 21, 2020
- ||| sotorasib (AMG 510) / Amgen
@DavidHongMD @MDAndersonNews KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors | NEJM https://t.co/dwuqZbconH (Twitter) - Sep 21, 2020
- |||| sotorasib (AMG 510) / Amgen
Clinical: Day2 #ESMO20 #OncoAlertTopTweet 🚨 AMG510 data on KRAS G12C (13% #lcsm) promising data in 59 pts, mFU 11.7 m, diarrhea 25%, fatigue/nausea 10%, ORR 32%, DCR 88%, median duration of response 10.9 m, responses even in STK11 co-mutated tumors. Tweet @jsoriamd @weoncologists (Twitter) - Sep 20, 2020
- |||||| sotorasib (AMG 510) / Amgen
Clinical: With promising results of #sotorasib (#AMG510 | @Amgen) presented at @myESMO #ESMO20, #KRASG12C is no longer non-druggable. Q: How often does it occur in our tumours? Sharing recent landscape analysis of #KRASG12C in #Chinese pts. https://t.co/G8L8bh63Br @TonyMok9 @CUHKMedicine (Twitter) - Sep 20, 2020
- ||| sotorasib (AMG 510) / Amgen
Day2 #ESMO20 #OncoAlertTopTweet 🚨 #CodeBreak100 sotorasib in #KRAS MT #NSCLC ORR 32,2% Median DOR 10.9mos #LungCancer #LCSM Tweet @CharuAggarwalMD @weoncologists (Twitter) - Sep 20, 2020
- |||| sotorasib (AMG 510) / Amgen
Clinical: Pretty neat that @cityofhope / @mgfakih is working with others to test safety/efficacy of sotorasib (AMG 510), which could become the first treatment for the “undruggable” cancer-causing KRAS fam of genes (KRAS G12C). Dr. Fakih is quoted in @BioPharmaDive https://t.co/Ui6KezKJBa (Twitter) - Sep 20, 2020
- |||| sotorasib (AMG 510) / Amgen
Clinical: Day2 #ESMO20 #OncoAlertTopTweet 🚨 Sotorasib activity in pretreated patients with #NSCLC #LungCancer #LCSM Tweet @BenjaminBesseMD @weoncologists (Twitter) - Sep 20, 2020
- | sotorasib (AMG 510) / Amgen
Sotorasib bonds covalently with the sulfur on the cysteine; G12 anything else will be a new challenge (Twitter) - Sep 20, 2020
- ||| sotorasib (AMG 510) / Amgen, docetaxel / Generic mfg.
Clinical: Agree. Let’s , me as first one, be more realistic. This was never meant to be selper-praseltinib like drug. If sotorasib proved to be better then Taxotere it would be anyway a great result and a great step forward for us and patients with kras G12c mut (Twitter) - Sep 20, 2020
- ||||| sotorasib (AMG 510) / Amgen
Clinical: For patients with #KRAS G12C-mutant #non-small cell #lung #cancer, sotorasib resulted in #tumor #shrinkage of 88.1%. Learn more about the findings presented at the 2020 ESMO Virtual Congress: https://t.co/jjsj8dV7x9 @DavidHongMD #ESMO20 #EndCancer (Twitter) - Sep 20, 2020
- |||||| @Amgen @VerastemOncolog @danwpaterson Can it be this easy? 😎 1.AMG510 / VS-6766 (RAS /RAF /MEK /ERK) +/- Defactinib (FAK) 2. AMG510 / Vs-5584 (PI3K mTOR) https://t.co/VDN8PpYoQW (Twitter) - Sep 20, 2020
- || sotorasib (AMG 510) / Amgen
Welcome to the world Sotorasib...to the first world... in the developing countries (LMIC) we will wait for your old age! (Twitter) - Sep 20, 2020
- |||| sotorasib (AMG 510) / Amgen
Sotorasib KRAS G12 C inhibitor presentation @myESMO #ESMO20 ➡️Responses seen across co-mutations. Looking forward for combo trials @CancerMedMDA @MDAndersonNews (Twitter) - Sep 20, 2020
- ||| sotorasib (AMG 510) / Amgen
Clinical: In first line absolutely with chemo.Not sure sotorasib could easily be combined with IO. (Twitter) - Sep 20, 2020
- ||| sotorasib (AMG 510) / Amgen
Sotorasib Shows Encouraging Antitumor Activity in Advanced NSCLC. @DavidHongMD @MDAndersonNews @myESMO #ESMO20 #lcsm https://t.co/0w4IIqR8VC (Twitter) - Sep 20, 2020
- |||| sotorasib (AMG 510) / Amgen
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors | NEJM congratulations @sloan_kettering Dr. Bob Li https://t.co/FuCi2RHOS0 (Twitter) - Sep 20, 2020
- ||| sotorasib (AMG 510) / Amgen
Wonderful to see the effect of sotorasib for "undruggable" KRAS G12C. Congrats to @DavidHongMD @MDAndersonNews and entire sotorasib team!! #ESMO20 @OncoAlert (Twitter) - Sep 20, 2020
- |||| sotorasib (AMG 510) / Amgen
Pan Tumor: Pan-tumor NEJM publication of sotorasib in KRAS G12C+ alongside today's #ESMO20 presentation in NSCLC. https://t.co/Fadc6MvXc4 #LCSM #CRCSM @DavidHongMD (Twitter) - Sep 20, 2020
- ||||| sotorasib (AMG 510) / Amgen, docetaxel / Generic mfg.
Clinical, P3 data: #ESMO20 Sotorasib was safe and effective in #KRAS G12C NSCLC. Safety profile will allow for combinations: what are the right partners? Can we combine with IO? Do we need a phase III vs docetaxel? @mylovelypinata says absolutely, we do. And other KRAS mutations being targeted too! (Twitter) - Sep 20, 2020
- ||||| MRTX849 / Mirati, sotorasib (AMG 510) / Amgen
#ESMO20 Well done discussion by Dr. Colin Lindsay who wins for most random @Twitter handle - @mylovelypinata. Helpful reminder of the journey leading to direct #KRAS inhibitors and the achievements of medicinal chemistry leading to agents like AMG 510 and MRTX849. #LCSM (Twitter) - Sep 20, 2020
- |||||| sotorasib (AMG 510) / Amgen
P2 data: Dear Dr. Hong, thank you for your excellent presentation at 2020 ESMO Congress. Great data on sotorasib for KRAS G12C mutant tumors. Next step: phase II. @IASLC @kRasKickers (Twitter) - Sep 20, 2020
- |||| sotorasib (AMG 510) / Amgen
Clinical: No better example of advances in medicinal chemistry and drug design than the advent of kras G12C inhibitors. The number of grants written for “kras” and “undruggable” could fill libraries. AMG510 (sotorasib) very active in this difficult population esp mNSCLC. IO combo next? (Twitter) - Sep 20, 2020
- ||| sotorasib (AMG 510) / Amgen
Clinical: Nice thread on AMG510 efficacy in KRAS G12C mutated NSCLC. #ESMO20 (Twitter) - Sep 20, 2020
- |||| sotorasib (AMG 510) / Amgen
Clinical: Sotorasib (AMG510) data in KRAS G12C pts released in NEJM. RR & PFS in NSCLC 32% and 6.3 m, 7% and 4.0 m in CRC. A big milestone! Next step: enhancing activity through combination Rx, especially in CRC. Delighted to be part of this journey. @cityofhope https://t.co/4Jl9zVvWxH (Twitter) - Sep 20, 2020
- |||| sotorasib (AMG 510) / Amgen
Clinical: Presented today at #ESMO20. Proud of the work of my #Phase1 team and global team of coauthors who worked on this trial despite a #pandemic. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors | NEJM @FoxChaseCancer #ittakesavillage https://t.co/gIPGPxu0t8 (Twitter) - Sep 20, 2020
- ||| sotorasib (AMG 510) / Amgen
🥁🥁🥁Finally KRAS is druggable. Even the Mighty KRAS falls to #PrecisionMedicine 👉KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors @NEJM Congratulations to @DavidHongMD & colleagues @MDAndersonNews @myESMO #ESMO20 https://t.co/QjiVy74lbf (Twitter) - Sep 20, 2020
- ||| sotorasib (AMG 510) / Amgen
Clinical: I know, but at least in the US AMG510 will be approved within the next 12 months, and with that, a number of patients might receive it off trial (Twitter) - Sep 20, 2020
- |||| sotorasib (AMG 510) / Amgen
Clinical: AMG-510 (Sotorasib) demonstrates durable benefit for patients with KRAS G12C mutant lung cancer. Definitely anxious to see how it will perform in the diverse upcoming PhIII trials. @OncoAlert @DavidHongMD @myESMO (Twitter) - Sep 20, 2020
- ||| sotorasib (AMG 510) / Amgen
Ready for the update on sotorasib by @DavidHongMD at #ESMO20! Read the recent spotlight on KRAS G12C inhibitors by @KlempnerSam and Aaron Hata in @CD_AACR: https://t.co/mHV2Mf1au7 (Twitter) - Sep 20, 2020
- |||| amivantamab (JNJ-61186372) / Genmab, J&J, sotorasib (AMG 510) / Amgen, lazertinib (GNS-1480) / Yuhan, J&J, Oscotec
Combination therapy: Terrific session on Sotorasib, and Amivantamab + Lazertinib @myESMO #ESMO20 Many ?s remain: > Resistance mechanisms before & after A + L? > Should A + L be 1st line? > Are we going back to IV therapies for targetable MT? > Combination therapy of S + IO in KRAS MT NSCLC? #LCSM (Twitter) - Sep 20, 2020
- ||||| sotorasib (AMG 510) / Amgen, docetaxel / Generic mfg.
Clinical, P3 data: Sotorasib (AMG510), first-in-class KRAS G12C inhibitor: activity in pretreated pts with NSCLC. -Best ORR: PR 35.3% - PD (=primary resistance) 5.9% -PFS 6.3 m -Favorable toxicity profile Should outperform docetaxel in the ongoing 2nd line post CT-IO phase III trial. #ESMO20 #LCSM (Twitter) - Sep 20, 2020
- |||||| MRTX849 / Mirati, sotorasib (AMG 510) / Amgen
Clinical: #ESMO20 very timely @CD_AACR 🔦<soto-RAS-ib> KRAS-G12C⛔️. We have several #clinicaltrials now open. Implications for many tumor types. The @CD_AACR 📝 sotorasib-AMG-510 @AmgenOncology & the MRTX849 compound from Mirati. More compounds also from other companies. @OncoAlert https://t.co/w1c8W342Ws (Twitter) - Sep 20, 2020
- ||||| sotorasib (AMG 510) / Amgen
Clinical: For patients with KRAS G12C-mutant non-small cell lung cancer, sotorasib resulted in tumor shrinkage of 88.1%. Learn more about the findings presented at the 2020 ESMO Virtual Congress: https://t.co/llXx2jA6C1 @DavidHongMD #ESMO20 #EndCancer (Twitter) - Sep 20, 2020
- ||||| sotorasib (AMG 510) / Amgen
Clinical: Sotorasib in KRASMT #NSCLC @myESMO #ESMO20 - 59 pts with NSCLC, 34 treated at 960 mg - G3/4 in ~18%, diarrhea in about 25% - ORR 32.2.%, median DOR 10.9 mos - Activity in STK11MT as well, and across different mutations - Promising drug, excellent presentation #LCSM (Twitter) - Sep 20, 2020
- |||||| sotorasib (AMG 510) / Amgen
Clinical, PD(L)-1 Biomarker, IO Biomarker: #ESMO20 AMG510 data on KRAS G12C (13% #lcsm) promising data in 59 pts, mFU 11.7 m, diarrhea 25%, fatigue/nausea 10%, ORR 32%, DCR 88%, median duration of response 10.9 m, responses even in STK11 co-mutated tumors. Response not related to KRAS AF, PDL1 or TMB or co-mutations (Twitter) - Sep 20, 2020